Triamcinolone Acetonide Nasal Spray

DEFINITION
Triamcinolone Acetonide Nasal Spray is an aqueous suspension of Triamcinolone Acetonide. It is supplied in a form suitable for nasal administration. It contains NLT 90.0% and NMT 110.0% of the labeled amount of triamcinolone acetonide (C$_{24}$H$_{31}$FO$_6$).

IDENTIFICATION
• A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
• B. The UV spectrum of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY
• Procedure
  Buffer A: 3.4 g/L of monobasic potassium phosphate prepared as follows. Dissolve 3.4 g of monobasic potassium phosphate in 900 mL of water, adjust with 5 M sodium hydroxide to a pH of 7.0, and dilute with water to 1000 mL.
  Buffer B: 3.4 g/L of monobasic potassium phosphate prepared as follows. Dissolve 3.4 g of monobasic potassium phosphate in 900 mL of water, adjust with phosphoric acid to a pH of 3.0, and dilute with water to 1000 mL.
  Solution A: Acetonitrile and Buffer A (27.5: 72.5)
  Solution B: Acetonitrile and Buffer A (60:40)
  Mobile phase: See Table 1.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Solution A (%)</th>
<th>Solution B (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>30</td>
<td>60</td>
<td>40</td>
</tr>
<tr>
<td>30.1</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>44</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>44.1</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>52</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Diluent: Acetonitrile and Buffer B (27.5: 72.5)
Standard stock solution: 0.4 mg/mL of USP Triamcinolone Acetonide RS in acetonitrile. Sonication for 15 min may be used to aid in dissolution.
Standard solution: 40 µg/mL of USP Triamcinolone Acetonide RS from Standard stock solution in Diluent
System suitability stock solution: 0.04 mg/mL of USP Triamcinolone Acetonide Related Compound B RS and USP Triamcinolone Acetonide Related Compound C RS in Diluent
System suitability solution: 40 µg/mL of USP Triamcinolone Acetonide RS and 0.8 µg/mL each of USP Triamcinolone Acetonide Related Compound B RS and USP Triamcinolone Acetonide Related Compound C RS in Diluent
RS from suitable volumes of Standard stock solution and System suitability stock solution in Diluent.

Sample solution: Nominally 40 µg/mL of triamcinolone acetonide prepared as follows. Discharge the contents of NLT 5 units of Nasal Spray to a suitable container. Transfer a portion of the Nasal Spray, equivalent to 4 mg of triamcinolone acetonide, to a 100-mL volumetric flask. Dissolve in 28 mL of acetonitrile with the aid of sonication. Allow to cool to room temperature and dilute with Buffer B to volume. Sonicate, if necessary. Centrifuge and use the clear supernatant [Note—Centrifuging at 3600 rpm for 30 min may be suitable.]

Chromatographic system
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 239 nm. For Identification B, use a diode array detector in the range of 210–400 nm.
Column: 4.6-mm × 25-cm; 5-µm packing L1
Column temperature: 40°
Flow rate: 0.75 mL/min
Injection volume: 100 µL
System suitability
Samples: Standard solution and System suitability solution
[Note—See Table 4 for the relative retention times.]
Suitability requirements
Resolution: NLT 3.0 between triamcinolone acetonide related compound C and triamcinolone acetonide related compound B; NLT 3.0 between triamcinolone acetonide related compound B and triamcinolone acetonide, System suitability solution
Tailing factor: NMT 1.3 for triamcinolone acetonide, System suitability solution
Relative standard deviation: NMT 1.0%, Standard solution
Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of the labeled amount of triamcinolone acetonide \( (\text{C}_{24}\text{H}_{31}\text{FO}_6) \) in the portion of Nasal Spray taken:

\[
\text{Result} = \left( \frac{r_U}{r_S} \right) \times \left( \frac{C_S}{C_U} \right) \times 100
\]

\( r_U \) = peak response from the Sample solution
\( r_S \) = peak response from the Standard solution
\( C_S \) = concentration of USP Triamcinolone Acetonide RS in the Standard solution (µg/mL)
\( C_U \) = nominal concentration of triamcinolone acetonide in the Sample solution (µg/mL)

Acceptance criteria: 90.0%–110.0%

OTHER COMPONENTS
• Content of Edetate Disodium
Perform this test if edetate disodium is a known component in the Nasal Spray.
Buffer: Add 990 mL of water into a 1000-mL beaker, followed by 10.0 mL of 1.0 M tetrabutylammonium hydroxide in methanol. Adjust with phosphoric acid to a pH of 7.0.
Mobile phase: Acetonitrile and Buffer (15:85)
Solution A: 40 g/L of sodium chloride and 2 g/L of sodium acetate. Adjust with glacial acetic acid to a pH of 5.5.
Solution B: 1.0 g/L of cupric sulfate in water
Diluent: Acetonitrile and water (50:50)
Standard stock solution: 0.5 mg/mL of edetate disodium in water. Sonication may be used to aid in dissolution.

Standard solution: 0.05 mg/mL of edetate disodium. Transfer 5.0 mL of Standard stock solution to a 50-mL volumetric flask. Next add 10 mL of Solution A and then add 5.0 mL of acetonitrile. Mix the resulting solution and then add 20.0 mL of Solution B, dilute with Diluent to volume, and mix.

Sample solution: Combine the contents of NLT 5 units of Nasal Spray and mix the contents to obtain a composite suspension. Transfer a 5.0-g portion of the Nasal Spray to a 50-mL volumetric flask. Add 10 mL of Solution A and 5.0 mL of acetonitrile. Mix and sonicate for 10 min and allow the solution to equilibrate to room temperature. Add 20.0 mL of Solution B, and sonicate for 10 min. Allow the sample to equilibrate to room temperature and dilute with Diluent to volume. Centrifuge a portion for 15 min, and use the supernatant. [Note—Centrifuging at 4000 rpm for 15 min may be suitable.]

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 265 nm
Column: 4.1-mm × 15-cm; 5-µm packing L21
Flow rate: 1 mL/min
Injection volume: 25 µL

System suitability
Sample: Standard solution
Suitability requirements
Tailing factor: NMT 2.0
Relative standard deviation: NMT 2.0%

Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of edetate disodium (C_{10}H_{14}N_{2}Na_{2}O_{8}) in the portion of Nasal Spray taken:

\[
\text{Result} = \left( \frac{r_U}{r_S} \right) \times C_S \times \left( \frac{V}{W} \right) \times 100
\]

\[r_U\] = peak response from the Sample solution
\[r_S\] = peak response from the Standard solution
\[C_S\] = concentration of edetate disodium in the Standard solution (mg/mL)
\[V\] = volume of the Sample solution (mL)
\[W\] = weight of Nasal Spray in the Sample solution (mg)

Acceptance criteria: 0.045%–0.055%

Change to read:

Content of Benzalkonium Chloride
Perform this test if benzalkonium chloride is a known component in the Nasal Spray.

Buffer: Dissolve 10.8 g of monobasic sodium phosphate dihydrate in 90 mL of water, and adjust with phosphoric acid to a pH of 2.5. Dilute with water to 100 mL.

Solution A: Mix 50 mL of Buffer, 750 mL of water, and 200 mL of methanol. Add 5 mL of triethylamine. Mix and adjust with phosphoric acid to a pH of 2.5.

Solution B: Mix 1 L of methanol with 50 mL of phosphoric acid.

Mobile phase: See Table 2.

Table 2
<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Solution A (%)</th>
<th>Solution B (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>3.0</td>
<td>5</td>
<td>95</td>
</tr>
<tr>
<td>3.2</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>5.0</td>
<td>55</td>
<td>45</td>
</tr>
</tbody>
</table>

Diluent: 1% (v/v) hydrochloric acid in methanol

System suitability solution: 0.04 mg/mL of USP Benzalkonium Chloride RS\* (IRA 1-Mar-2021) prepared as follows. Transfer a suitable volume of USP Benzalkonium Chloride RS to a suitable volumetric flask and add 30% of the flask volume of water. Dilute with Diluent to volume.\* (IRA 1-Mar-2021)

Standard stock solution: 0.04 mg/mL of USP Benzalkonium Bromide RS in water. [Note—A few drops of methanol may be used to resolve the formation of foam prior to dilution.]

Standard solution: 0.04 mg/mL of USP Benzalkonium Bromide RS. Transfer an aliquot of Standard stock solution to a suitable volumetric flask, and add water equal to 30% of the flask volume. Dilute with Diluent to volume.

Sample solution: Combine the contents of NLT 5 units of Nasal Spray and mix the contents to obtain a composite suspension. Transfer a 5.0-g portion of the Nasal Spray to a 10-mL volumetric flask. Dilute with Diluent to volume. Centrifuge and use the supernatant. [Note—Centrifuging at 4000 rpm for 15 min may be suitable. The supernatant may be passed through a suitable filter of NMT 0.2-µm pore size.]

Chromatographic system
(See Chromatography (621), System Suitability.)

- **Mode:** LC
- **Detector:** UV 210 nm
- **Column:** 4.6-mm × 3.0-cm; 2.6-µm packing L1
- **Column temperature:** 50°
- **Flow rate:** 2 mL/min
- **Injection volume:** 100 µL

System suitability

- **Samples:** System suitability solution and Standard solution
  [Note—See Table 3 for the relative retention times. The peak due to the C10 analog may not be visible due to its low concentration in the System suitability solution. The Standard solution may contain only one peak as it is predominantly the C12 analog.]

Suitability requirements

- **Resolution:** NLT 2.5 between the pairs of C12 and C14 homologs and C14 and C16 homologs of benzalkonium, System suitability solution
- **Tailing factor:** NMT 2.0, Standard solution
- **Relative standard deviation:** NMT 2%, Standard solution

Analysis

- **Samples:** Standard solution and Sample solution

  Calculate the sum of the corrected benzalkonium peak responses (r<sub>CU</sub>) in the portion of Sample solution taken:

\[
\text{Result} = \Sigma [r_U \times (1/F)]
\]

\[r_U = \text{peak response of each benzalkonium homolog from the Sample solution}\]
\[ F = \text{relative response factor of the corresponding benzalkonium homolog relative to benzalkonium bromide (see Table 3)} \]

**Table 3**

<table>
<thead>
<tr>
<th>Benzalkonium Chloride Analog</th>
<th>Relative Retention Time</th>
<th>Relative Response Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>C10</td>
<td>0.65</td>
<td>1.3</td>
</tr>
<tr>
<td>C12</td>
<td>1.0</td>
<td>1.2</td>
</tr>
<tr>
<td>C14</td>
<td>1.35</td>
<td>1.0</td>
</tr>
<tr>
<td>C16</td>
<td>1.59</td>
<td>0.98</td>
</tr>
</tbody>
</table>

Calculate the percentage of benzalkonium chloride in the portion of Nasal Spray taken:

\[
\text{Result} = \left( \frac{r_{CU}}{r_S} \right) \times C_S \times \left( \frac{V}{W} \right) \times 100
\]

\[ r_{CU} = \text{sum of the corrected peak responses of the benzalkonium homologs from the Sample solution} \]
\[ r_S = \text{peak response of benzalkonium from the Standard solution} \]
\[ C_S = \text{concentration of USP Benzalkonium Bromide RS in the Standard solution (mg/mL)} \]
\[ V = \text{volume of the Sample solution (mL)} \]
\[ W = \text{weight of Nasal Spray in the Sample solution (mg)} \]

Acceptance criteria: 0.0135%–0.0165%

**PERFORMANCE TESTS**

- **Delivered Dose Uniformity (Between Units)**

  **Buffer:** 7.0 g/L of sodium perchlorate prepared as follows. Dissolve 7.0 g of sodium perchlorate in 900 mL of water, adjust with perchloric acid to a pH of 3.0, and dilute with water to 1000 mL.

  **Mobile phase:** Acetonitrile and Buffer (50:50)

  **Standard solution:** 40 µg/mL of USP Triamcinolone Acetonide RS in Mobile phase

  **Sample solution:** Nominally 40 µg/mL of triamcinolone acetonide prepared as follows. Transfer a portion of Nasal Spray, equivalent to 4.0 mg of triamcinolone acetonide, to a suitable volumetric flask. Add Mobile phase to 80% of the flask volume. Sonicate for 15 min. Allow to equilibrate to room temperature. Dilute with Mobile phase to volume. Centrifuge and pass the supernatant through a filter of 0.45-µm pore size. [Note—Centrifuging at 4000 rpm for 45 min may be suitable.]

  Repeat this procedure with 9 additional units.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 239 nm

**Column:** 4.6-mm × 15-cm; 5-µm packing L1

**Flow rate:** 1 mL/min

**Injection volume:** 40 µL

**System suitability**

**Sample:** Standard solution

**Suitability requirements**
**Tailing factor:** NMT 2.0  
**Relative standard deviation:** NMT 1.0%

### Analysis

**Samples:** Standard solution and Sample solution  
Calculate the percentage of the labeled amount of triamcinolone acetonide \( (C_{24}H_{31}FO_6) \) in the portion of Nasal Spray taken:

\[
\text{Result} = \left( \frac{r_U}{r_S} \right) \times \left( \frac{C_S}{C_U} \right) \times 100
\]

- \( r_U \) = peak response from the Sample solution  
- \( r_S \) = peak response from the Standard solution  
- \( C_S \) = concentration of USP Triamcinolone Acetonide RS in the Standard solution (µg/mL)  
- \( C_U \) = nominal concentration of triamcinolone acetonide in the Sample solution (µg/mL)

### Acceptance criteria

**Tier 1:** The content of each of the 10 units is within 90.0%–110.0% of the labeled amount of triamcinolone acetonide \( (C_{24}H_{31}FO_6) \).

If the criterion in Tier 1 cannot be met, proceed to Tier 2.

**Tier 2:** If the content of 1 unit is outside 90.0%–110.0% of the labeled amount of triamcinolone acetonide \( (C_{24}H_{31}FO_6) \) and the content of none of the units is outside 85.0%–115.0% of the labeled amount of triamcinolone acetonide \( (C_{24}H_{31}FO_6) \), test an additional 20 units. All 30 of the results (including the results from Tier 1) meet the following acceptance criteria.

1. The content of each of 29 out of 30 units is within 90.0%–110.0% of the labeled amount of triamcinolone acetonide \( (C_{24}H_{31}FO_6) \).
2. The content of each of the 30 units is within 85.0%–115.0% of the labeled amount of triamcinolone acetonide \( (C_{24}H_{31}FO_6) \).

### Delivered Dose Uniformity (Within Unit)

**Buffer:** 7.0 g/L of sodium perchlorate prepared as follows. Dissolve 7.0 g of sodium perchlorate in 900 mL of water, adjust with perchloric acid to a pH of 3.0, and dilute with water to 1000 mL.

**Mobile phase:** Acetonitrile and Buffer (50:50)

**Standard solution:** 4.8 µg/mL of USP Triamcinolone Acetonide RS in Mobile phase

**Beginning sample solution (BOU):** Hold the pump upright, actuate 5 times, and wipe the nosepiece dry. Hold a 25-mL volumetric flask in an inverted position and actuate the pump. Quickly turn the flask upright, wait 10 s, and repeat the process. Add 15 mL of Mobile phase while rinsing the neck of the flask and sonicate for 15 min. Allow the flask to equilibrate to room temperature, and dilute with Mobile phase to volume. Centrifuge and use the clear supernatant. This is the BOU sample. [Note—Centrifuging at 4000 rpm for 15 min may be suitable.]

**Middle sample solution (MOU):** Using the same pump as above, discharge an appropriate number of actuations to arrive at 50% of the labeled number of actuations to waste and wipe the nosepiece dry. Hold a 25-mL volumetric flask in an inverted position and actuate the pump to collect the next actuation. Quickly turn the flask upright, wait 10 s, and repeat the process to collect the next actuation. Add 15 mL of Mobile phase while rinsing the neck of the flask and sonicate for 15 min. Allow the flask to equilibrate to room temperature, and dilute with Mobile phase to volume. Centrifuge and use the clear supernatant. This is the MOU sample. [Note—Centrifuging at 4000 rpm for 15 min may be suitable.]
End sample solution (EOU): Using the same pump as above, discharge the next appropriate number of actuations to arrive at 100% of the labeled number of actuations to waste, and wipe the nosepiece dry. Hold a 25-mL volumetric flask in an inverted position and actuate the pump to collect the next actuation. Quickly turn the flask upright, wait 10 s, and repeat the process to collect the next actuation. Add 15 mL of Mobile phase while rinsing the neck of the flask and sonicate for 15 min. Allow the flask to equilibrate to room temperature, and dilute with Mobile phase to volume. Centrifuge and use the clear supernatant. This is the EOU sample. [Note—Centrifuging at 4000 rpm for 15 min may be suitable.]

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 239 nm
Column: 4.6-mm × 15-cm; 5-µm packing L1
Flow rate: 1 mL/min
Injection volume: 200 µL

System suitability
Sample: Standard solution
Suitability requirements
  Tailing factor: NMT 2.0
  Relative standard deviation: NMT 1.0%

Analysis
Samples: Standard solution, Beginning sample solution, Middle sample solution, and End sample solution
Calculate the percentage of the labeled amount of the triamcinolone acetonide (C_{24}H_{31}FO_{6}) delivered dose:

\[
\text{Result} = \left( \frac{r_U}{r_S} \right) \times \left( \frac{C_S}{C_U} \right) \times 100
\]

- \( r_U \) = peak response from the appropriate Sample solution
- \( r_S \) = peak response from the Standard solution
- \( C_S \) = concentration of USP Triamcinolone Acetonide RS in the Standard solution (µg/mL)
- \( C_U \) = nominal concentration of triamcinolone acetonide in the appropriate Sample solution (µg/mL)

Acceptance criteria
Calculate the mean delivered dose from the BOU results from all 10 units.
Calculate the mean delivered dose from the MOU results from all 10 units.
Calculate the mean delivered dose from the EOU results from all 10 units.
Calculate the unit delivery mean from the BOU, MOU, and EOU results from each of the 10 units.

Tier 1:

1. Mean delivered dose of BOU samples from all 10 units is within 85.0%–115.0% of the labeled amount of triamcinolone acetonide (C_{24}H_{31}FO_{6}).
2. Mean delivered dose of MOU samples from all 10 units is within 85.0%–115.0% of the labeled amount of triamcinolone acetonide (C_{24}H_{31}FO_{6}).
3. Mean delivered dose of EOU samples from all 10 units is within 85.0%–115.0% of the labeled amount of triamcinolone acetonide (C_{24}H_{31}FO_{6}).
4. NMT 1 unit delivery mean from the 10 units is outside 80.0%–120.0% of the labeled amount of triamcinolone acetonide (C_{24}H_{31}FO_{6}).
5. None of the unit delivery means from the 10 units is outside 75.0%–125.0% of the labeled amount of triamcinolone acetonide (C_{24}H_{31}FO_{6}).
**Tier 1** criteria 1–3 must be met. If criterion 4 or 5 cannot be met, proceed to **Tier 2**.

**Tier 2:** If NMT 3 unit delivery means are outside 80.0%–120.0% of the labeled amount of triamcinolone acetonide \((C_{24}H_{31}FO_6)\) and none of the unit delivery means is outside 75.0%–125.0% of the labeled amount of triamcinolone acetonide \((C_{24}H_{31}FO_6)\), test an additional 20 units. All 30 unit delivery means (including the results from **Tier 1**) meet the following acceptance criteria.

1. NMT 3 of 30 unit delivery means are outside 80.0%–120.0% of the labeled amount of triamcinolone acetonide \((C_{24}H_{31}FO_6)\).
2. None of the 30 unit delivery means is outside 75.0%–125.0% of the labeled amount of triamcinolone acetonide \((C_{24}H_{31}FO_6)\).

**IMPURITIES**

**Organic Impurities**


**Analysis**

Sample: Sample solution

Calculate the percentage of each degradation product in the portion of Nasal Spray taken:

\[
\text{Result} = \left( \frac{r_I}{r_U} \right) \times 100
\]

\(r_I\) = peak response of each degradation product from the Sample solution

\(r_U\) = peak response of triamcinolone acetonide from the Sample solution

**Acceptance criteria:** See Table 4. Disregard any peak below 0.05%.

**Table 4**

<table>
<thead>
<tr>
<th>Name</th>
<th>Relative Retention Time</th>
<th>Acceptance Criteria, NMT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triamcinolone acetonide ketoacid derivative</td>
<td>0.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Triamcinolone acetonide related compound C</td>
<td>0.83</td>
<td>2.8</td>
</tr>
<tr>
<td>Triamcinolone acetonide related compound B</td>
<td>0.91</td>
<td>0.4</td>
</tr>
<tr>
<td>Triamcinolone acetonide</td>
<td>1.0</td>
<td>—</td>
</tr>
<tr>
<td>Any other individual degradation product</td>
<td>—</td>
<td>0.1</td>
</tr>
<tr>
<td>Total degradation products</td>
<td>—</td>
<td>3.4</td>
</tr>
</tbody>
</table>

\(a\) 9-Fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(11β,16α)-3,20-dioxopregna-1,4-diene-21-oic acid.

**SPECIFIC TESTS**

- **pH** \((791)\): 4.5–6.0
- **Microbial Enumeration Tests** \((61)\) and **Tests for Specified Microorganisms** \((62)\): It meets the requirements of the tests for absence of *Staphylococcus aureus*, *Escherichia coli*, *Salmonella* species, and
*Pseudomonas aeruginosa.* The total aerobic microbial count is NMT 10^1 cfu/mL and the total combined molds and yeasts count is NMT 10^1 cfu/mL.

- **Particle Size**
  
  **Analysis:** Shake the Nasal Spray and prime the pump by spraying 3–4 times. Actuate the spray and collect the sample on a glass microscope slide held above the nozzle, and repeat to prepare a second slide. Using light microscopy, determine the dimension of NLT 200 particles of triamcinolone acetonide by measuring NLT 100 particles from 20 random fields of view for each slide prepared. Repeat the procedure using a second unit of Nasal Spray.

  **Acceptance criteria:** See *Table 5.*

  **Table 5**

<table>
<thead>
<tr>
<th>Particle Size (µm)</th>
<th>Acceptance Criteria (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>NMT 3</td>
</tr>
<tr>
<td>1–6</td>
<td>70–95</td>
</tr>
<tr>
<td>&gt;9</td>
<td>NMT 4</td>
</tr>
</tbody>
</table>

**Additional Requirements**

- **Packaging and Storage:** Preserve in a tight, light-resistant container, and store at controlled room temperature.

  **USP Reference Standards (11):**
  
  - USP Benzalkonium Bromide RS
  - USP Benzalkonium Chloride RS
  - USP Triamcinolone Acetonide RS
  - USP Triamcinolone Acetonide Related Compound B RS
  - USP Triamcinolone Acetonide Related Compound C RS

  9-Fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(11β,16α)-pregna-1,4,14-triene-3,20-dione.

  \[C_{24}H_{29}FO_6\] 432.48

  9-Fluoro-11,21,21-trihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(11β,16α)-pregna-1,4-diene-3,20-dione.

  \[C_{24}H_{31}FO_7\] 450.50

**Page Information:**

Not Applicable

**DocID:** © 2021 The United States Pharmacopeial Convention All Rights Reserved.